Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases
Marwan Ghabril, Herbert L. Bonkovsky, Clarissa Kum et al. · Clinical Gastroenterology and Hepatology · 2013
Cited by 217 works. doi:10.1016/j.cgh.2012.12.025 Open-access PDF
Authors
- Marwan Ghabril
- Herbert L. Bonkovsky
- Clarissa Kum
- Tim Davern
- Paul Hideyo Hayashi
- David Erwin Kleiner
- José Serrano
- Jim Rochon
- Robert J. Fontana
- Maurizio Bonacini
References
- Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge
- Drug-Induced Autoimmune Hepatitis: Clinical Characteristics and Prognosis
- Drug-Induced Liver Injury
- A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis
- Standardization of nomenclature and causality assessment in drug‐induced liver injury
- A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Etanercept in the Treatment of Alcoholic Hepatitis
- Serious liver disease induced by infliximab
- Infliximab, but not etanercept, induces IgM anti–double‐stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritis
- Infliximab-Associated Reversible Cholestatic Liver Disease
- Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis